GI Innovation, Inc.
358570 · KOSDAQ
Public Market Listing
358570KOSDAQ
Live quotes, historical charts, and market capitalization for GI Innovation, Inc. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | CTLA-4 / IL-2RβγProtein / enzyme therapeutic | Non-Small Cell Lung Cancer | |
| Phase 1/2 | CTLA-4 / IL-2RβγProtein / enzyme therapeutic | Non-Small Cell Lung CancerCervical CancerRenal Cell CarcinomaBladder / Urothelial Cancer Clear Cell Renal Cell Carcinoma, Urothelial Carcinoma | |
| Phase 1/2 | CD73 / IL-2RβγMultispecific antibody | Non-Small Cell Lung Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
2028 (1)
June 2028 (1)
Efdelikofusp alfa + GI-101APhase 1/2Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma, Clear Cell Renal Cell Cancer (ccRCC) …
Est. primary completion 2028-06-30 · NCT04977453 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.